A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Histone deacetylase inhibitors (HDACi) have proven activity in hematologic malignancies, and their FDA approval in multiple myeloma (MM) and T-cell lymphoma highlights the need for further development of this drug class. We investigated AR-42, an oral pan-HDACi, in a first-in-man phase 1 dose escala...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Sborov, Douglas W., Canella, Alessandro, Hade, Erinn M., Mo, Xiaokui, Khountham, Soun, Wang, Jiang, Ni, Wenjun, Poi, Ming, Coss, Christopher, Liu, Zhongfa, Phelps, Mitch A., Mortazavi, Amir, Andritsos, Leslie, Baiocchi, Robert A., Christian, Beth A, Benson, Don M., Flynn, Joseph, Porcu, Pierluigi, Byrd, John C., Pichiorri, Flavia, Hofmeister, Craig C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5489371/
https://ncbi.nlm.nih.gov/pubmed/28270022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2017.1298751
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados